TNFRSF4 and neoplasm: To evaluate the antitumor therapeutic effect of combining VTP treatment with the combination immunotherapy, MB-49 UTUC allograft-bearing mice were treated with VTP on day 15 following tumor implantation and injected the following day with OX40 agonist and PD-1 inhibitor antibodies, as described above.